04 CU06 (Diabetic Macular Edema), U.S. Phase 2a Clinical Trial CSR(Clinical Study Reports) received

02 CU06 (Diabetic Macular Edema), U.S. Phase 2a Clinical Trial Topline Data Announced

12 CU104 (Ulcerative Colitis), Phase 2 IND application approved by the Europe

09 Co-development agreement with CAND to develop treatments for kidney disease of companion animals

06 Signed on MOU with MabTics, an antibody therapeutics company

06 CU104 (Ulcerative Colitis), Phase 2 IND application approved by the FDA

06 Signed an MOU with Center for Companion Animal New drug Development(CAND)

04 Signed MOU with College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

12 Acquired high-tech product certification from the Ministry of Trade, Industry and Energy

12 Grand Prize at the 2022 Korea Value Management Award by HANKOOKILBO

11 Acquired R&D type venture enterprise certification

09 CU06(diabetic macular edema), Phase 2a IND application approved

09 New CFO·Vice President Appointed

07 CU01(diabetic nephropathy), Phase 2a IND application approved

06 Computer-Aided drug design

CU06, Finalized CU06 Phase1 CSR

04 Relocated research center and welcomed Seocho Headquarters phase

01 Established 2nd bio research center

00 Signed on MOU with STANDIGM, an artificial intelligence (AI) drug discovery company

10 New CEO Appointed

CU06, Out-licensed to ophthalmology company Thea for 200 Billion USD

09 CU01 (Diabetic nephropathy), Submitted Phase 3 IND

07 Listed on KOSDAQ (365270)

03 Passed the technical evaluation for Special Technology Assessment Track listing(grade: AA, A)

CU01 (Diabetic nephropathy), Confirmed safety and efficacy in Phase 2a clinical trial

02 CU06 (Diabetic Macular Edema), Phase 1 IND approved by FDA (NCT04795037)

01 Signed MOU with College of Pharmacy & Institute of Pharmaceutical Science and Technology Research, Korea University

12 Signed research agreement with Severance Hospital

11 CU06 (Vessel Protector & Zipper) U.S. Clinical DP Production Completed (cGMP)

Signed research agreement with Yonsei University and opened industry-academic cooperation biolab

Inno-Biz certification (certification number: 200605–01197)

10 Introduction and Transition of Electronic Securities System

Funding raised (US$ 4 million)

08 Awarded ‘Bio-Tech Science Innovation Award’ from “2020 6th Korea Leading Enterprise Awards”

CU01 (Diabetic Nephropathy), Completed Test Subject Recruitment for Clinical 2a Phase

CU03 (Wet AMD), Completed Clinical 2a Phase tolerability Assessment, Recruited additional 60 subjects

Appointment of stock transfer agent (Korea Securities Depository)

06 Signed research agreement for formulation development with LS Pharma

04 Startups Research Infra Utilization (Research Focused) Grant awarded by the Ministry of SMEs

CU06, Pharmaceutical Industry Global Advancement Supporting Grant awarded by the Ministry of Health and Welfare

03 CU06, signed CMO service contract with Yuhan Chemical (South Korea) for cGMP DS production of FDA Phase 1 study

01 Established Bio & Analytical Laboratory at Pangyo 2nd Techno Valley

12 CU03 (Wet AMD), Phase 2a IND approved by Ministry of Food and Drug Safety(MFDS)

11 Signed Consultation contract with BL&H (USA) for global BD

Funding raised (US$ 7.1 million)

10 Relocated headquarters to Pangyo 2nd Techno Valley

CU06, signed CMO service contract with Patheon (USA) for formulation study & cGMP DP production

07 Samsung Securities selected as underwriter for IPO

06 CU06, Signed CRO service contract with Covance (UK) for global GLP nonclinical study

05 CU01 (Diabetic Nephropathy), Phase 2a IND approved by Ministry of Food and Drug Safety(MFDS)

04 CU06, Signed Technology transfer agreement of Vessel Protector & Zipper from Yonsei University

01 Relocated R&D center (from Daegu Gyeongbuk Medical Innovation Foundation (DGMIF) to Korea Research Institute of Chemical Technology (KRICT), Daejeon)

12 Nominated as a membership business of the Korea Research Institute of Chemical Technology (KRICT)

11 Funding raised (US$ 9.0 million)

10 Relocated headquarters (Woorim W-city at Pangyo)

03 CU05 (Lung Cancer), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business project

01 CU02 (NASH & Obesity), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business

10 CU04 (immunotherapy), Grant awarded by Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) New Drug Development Center for optimization support

08 CU02 (NASH & Obesity), Signed Technology transfer agreement from Gwangju Institute of Science and Technology (GIST), Korea Advanced Institute of Science and Technology (KAIST) & Kyungpook National University (KNU)

06 CU01, Grant awarded from the Ministry of Trade, Industry and Energy

05 CU01 Signed research contract with Mcnulty for formulation development

04 CU05, Signed research agreement with College of Pharmacy, Gachon University

03 CU03 (Macular Degeneration), Signed technology transfer agreement from Korea Institute of Oriental Medicine (KIOM)

02 CU01 (Renal Fibrosis), Signed technology transfer agreement from Kyungpook National University

CU05 (Lung Cancer), Signed technology transfer agreement from Yonsei University

01 Established R&D center at Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF) certified as affiliated research institute

11 Registered as a venture business (No. 20160300500)

Relocated headquarters (Innovalley at Pangyo)

10 Funding raised (US$ 1.5 million)

05 Established Curacle Co., Ltd. (Gangnam, Seoul)